VerheugtFWGrangerCB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet2015; 386: 303–310.
2.
ZirlikABodeC. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis2017; 43: 365–379.
3.
RuffCTGiuglianoRPBraunwaldE, et al.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet2014; 383: 955–962.
4.
KirchhofPBenussiSKotechaD, et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J2016; 37: 2893–2962.
5.
GrangerCBAlexanderJHMcMurrayJJ, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011; 365: 981–992.
6.
Berglund E, Wallentin L, Oldgren J, et al. Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial. Eur J Prev Cardiol. 2020; 27: 1311–1319.
7.
BottaiMZhangJ. Laplace regression with censored data. Biometrical J2010; 52: 487–503.
8.
LloydAJ. The extent of patients’ understanding of the risk of treatments. Qual Health Care2001; 10(Suppl. 1): i14–i18.
9.
DahlRGyrd-HansenDKristiansenIS, et al.Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey. BMC Med Inform Decis Mak2007; 7: 8–8.
10.
YaoXAbrahamNSAlexanderGC, et al.Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc2016; 5: 1–12.
11.
JortveitJPrippAHLangørgenJ, et al.Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. Eur J Prev Cardiol2019; 26: 1373–1382.
